Clinical trials in La Roche sur Yon – page 2

224 clinical trials in La Roche sur Yon, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

La Roche sur Yon at a glance

224

clinical trials

Paediatric trials0
Research sites1

Quick filters

224 trials in La Roche sur Yon

Open in trial search

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

France

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Interstitial lung disease

Recruiting

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Belimumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Acute kidney injury

Recruiting

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Cardiac amyloidosis

Recruiting

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational

France

Participants:18–64 years · 65+ years
Substances:Coramitug
Sponsor:Novo Nordisk A/S

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Ivonescimab
Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Contact Research Centre

Sepsis

Recruiting

Testing a Drug Combination for Personalized Sepsis Treatment in Children and Adults with Severe Blood Infection

Registered drugNo placebo

Testing a Drug Combination for Personalized Sepsis Treatment in Children and Adults with Severe Blood Infection

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anakinra
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Pleural mesothelioma

Recruiting

Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

Registered drugNo placebo

Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Renal cell carcinoma

Recruiting

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Breast cancer+2

Recruiting

A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

InvestigationalNo placebo

A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Datopotamab Deruxtecan
Sponsor:AstraZeneca AB

Contact Research Centre

Osteoarthritis

Recruiting

Study of Methotrexate Treatment for Patients with Erosive Hand Osteoarthritis Not Responding to Standard Therapy

Registered drug

Study of Methotrexate Treatment for Patients with Erosive Hand Osteoarthritis Not Responding to Standard Therapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Folic Acid
Sponsor:Centre Hospitalier Universitaire De Nice

Contact Research Centre

Bronchiolitis+1

Recruiting

Study of nirsevimab and RSV vaccine (Abrysvo) for prevention of respiratory syncytial virus infection in infants during their first year of life

Registered drugNo placebo

Study of nirsevimab and RSV vaccine (Abrysvo) for prevention of respiratory syncytial virus infection in infants during their first year of life

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Nirsevimab
Sponsor:Centre Hospitalier Annecy Genevois

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in La Roche sur Yon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, breast cancer, and colorectal cancer treatments. Studies include evaluation of new therapeutic combinations and maintenance strategies.

Advanced breast cancer therapies
Multiple myeloma treatments
Colorectal cancer interventions

Investigations include novel drug combinations and targeted therapies for various cancer types.

02 Immunology & Inflammatory Conditions

Research focusing on treatments for Crohn's disease, ulcerative colitis, and rheumatoid arthritis. Studies evaluate new therapeutic approaches for inflammatory conditions.

Inflammatory bowel diseases
Autoimmune disorders
Novel immunotherapy approaches

Trials aim to improve treatment outcomes for patients with chronic inflammatory conditions.

03 Cardiovascular & Metabolic Research

Studies examining treatments for heart failure prevention, chronic kidney disease, and related cardiovascular conditions. Focus on innovative therapeutic combinations.

Heart failure prevention
Kidney disease management
Cardiovascular outcomes

Investigation of new approaches to prevent and treat cardiovascular complications.

Back to France All countries